Premaitha Health has reeled in £2.5m in sales in the first full year of commercialisation of its IONA non-invasive prenatal test (NIPT) for Downs Syndrome.
During the year, the company made considerable progress in establishing an initial customer base of laboratories which are now processing tests for hospitals in the UK, Poland, Switzerland, France, Russia and the Middle East.
“The international landscape for non-invasive prenatal testing is evolving very considerably in Premaitha’s favour – with numerous countries moving towards making this safer testing procedure more freely and readily available through public health services. We expect the UK to soon make NIPT freely available to high risk women on the NHS and for other countries to follow suit.”
See the article in full at BusinessDesk.com